JUN 16, 2021 7:25 AM PDT

New drug attacks pancreatic tumors with mutant KRAS addiction

Pancreatic cancer is notoriously difficult to detect in early stages, which is why it is associated with a low survival rate. Now a study published in Clinical Cancer Research identifies a drug that is capable of derailing pancreatic tumors that are dependent on the mutant KRAS gene.

Approximately 90% of pancreatic cancers harbor mutant KRAS and some tumors have even been shown in previous studies to be unable to survive without the gene – what’s called a mutant KRAS addiction. Watch the video below to learn more about the KRAS gene and how it causes cancer.

In researching mutant KRAS addition, Said Sebti, Ph.D., who is associate director for basic research at VCU Massey Cancer Center, discovered a drug that can kill pancreatic tumors with mutant KRAS addiction. "We discovered a link between hyperactivation of the CDK protein and mutant KRAS addiction, and we exploited this link preclinically to counter mutant KRAS-driven pancreatic cancer, warranting clinical investigation in patients afflicted with this deadly disease," said Sebti. "Our findings are highly significant as they revealed a new avenue to combat an aggressive form of pancreatic cancer with very poor prognosis due mainly to its resistance to conventional therapies."

"Using three entirely different approaches, the same conclusion presented itself clearly to us: pancreatic cancer patients whose tumors are addicted to mutant KRAS could benefit greatly from treatment with the CDK inhibitor AT7519," Sebti adds.

Further tests showed that AT7519 was also able to suppress the growth of xenograft cells from five mutant KRAS pancreatic cancer patients who had not experienced success with chemotherapy and/or radiation. Next, the researchers hope to test out AT7519 in clinical trials targeting pancreatic cancer.

"If our findings are correct and translate in humans, then we should be able to see a positive response in pancreatic cancer patients whose tumors are addicted to mutant KRAS," Sebti said.

Sources: Clinical Cancer Research, Science Daily

About the Author
Bachelor's (BA/BS/Other)
Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 27, 2022
Clinical & Molecular DX
New Research Elucidates the Mechanism of Skin Cancer Metastasis to the Brain and Points to Groundbreaking Treatment
New Research Elucidates the Mechanism of Skin Cancer Metastasis to the Brain and Points to Groundbreaking Treatment
In advanced stages of skin cancer, patients develop brain metastases about 90% of the time. Though this is one of the mo ...
NOV 14, 2022
Cancer
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
Breast Cancer Vaccine Shows Promise as it Enters Phase 2 Trial
About 20% of breast cancers exhibit elevated levels of a protein known as HER2.  You may have heard the classifier ...
DEC 08, 2022
Cancer
Could a Drug for Parkinson's Disease Reduce the Side Effects of Chemotherapy?
Could a Drug for Parkinson's Disease Reduce the Side Effects of Chemotherapy?
Chemotherapies, drugs used to fight cancer by killing tumor cells or preventing them from growing and dividing, remain s ...
DEC 18, 2022
Cell & Molecular Biology
Scientists Reveal a Mechanism Underlying a Childhood Disease
Scientists Reveal a Mechanism Underlying a Childhood Disease
Langerhans cell histiocytosis (LCH) is a rare disorder that typically affects children, and can lead to many complicatio ...
DEC 20, 2022
Clinical & Molecular DX
Creatine Biomarker Could Be Used to Screen for Deadly Myocarditis After Cancer Treatment
Creatine Biomarker Could Be Used to Screen for Deadly Myocarditis After Cancer Treatment
Immune checkpoints are a part of the immune system that prevents the body’s immune response from destroying health ...
JAN 25, 2023
Cancer
Pregnancy After, or During, Breast Cancer
Pregnancy After, or During, Breast Cancer
Breast cancer remains the most common cancer in women in the United States.  Experts estimated 287,850 breast cance ...
Loading Comments...